60 Degrees Pharmaceuticals (NASDAQ:SXTP) Given Sell (E+) Rating at Weiss Ratings

Weiss Ratings reaffirmed their sell (e+) rating on shares of 60 Degrees Pharmaceuticals (NASDAQ:SXTP) in a report published on Saturday morning,Weiss Ratings reports.

Separately, HC Wainwright reissued a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a report on Friday, January 10th.

60 Degrees Pharmaceuticals Stock Performance

Shares of SXTP traded up $0.00 during mid-day trading on Friday, hitting $0.83. The company’s stock had a trading volume of 322,501 shares, compared to its average volume of 926,419. The stock’s 50-day moving average is $1.19 and its two-hundred day moving average is $1.02. The firm has a market capitalization of $1.90 million, a PE ratio of -0.08 and a beta of 4.40. 60 Degrees Pharmaceuticals has a one year low of $0.70 and a one year high of $11.01.

Insider Buying and Selling at 60 Degrees Pharmaceuticals

In other 60 Degrees Pharmaceuticals news, CEO Geoffrey S. Dow acquired 35,823 shares of 60 Degrees Pharmaceuticals stock in a transaction dated Monday, December 9th. The stock was bought at an average cost of $1.27 per share, with a total value of $45,495.21. Following the acquisition, the chief executive officer now owns 94,580 shares of the company’s stock, valued at approximately $120,116.60. The trade was a 60.97 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders bought a total of 66,372 shares of company stock valued at $82,410 in the last quarter. Corporate insiders own 10.27% of the company’s stock.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.